The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
APOBEC Deaminases
/ genetics
Adult
Aged
Aged, 80 and over
Alleles
Biomarkers, Tumor
/ metabolism
Clone Cells
DNA Copy Number Variations
/ genetics
Disease Progression
Evolution, Molecular
Female
Gene Expression Regulation, Neoplastic
Genes, Tumor Suppressor
Genome, Human
Humans
Male
Middle Aged
Multivariate Analysis
Mutation
/ genetics
Mutation Rate
Progression-Free Survival
Proto-Oncogene Proteins p21(ras)
/ genetics
Smoldering Multiple Myeloma
/ diagnosis
Time Factors
Translocation, Genetic
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
30
07
2020
accepted:
08
12
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
22
1
2021
Statut:
epublish
Résumé
Smoldering myeloma (SMM) is associated with a high-risk of progression to myeloma (MM). We report the results of a study of 82 patients with both targeted sequencing that included a capture of the immunoglobulin and MYC regions. By comparing these results to newly diagnosed myeloma (MM) we show fewer NRAS and FAM46C mutations together with fewer adverse translocations, del(1p), del(14q), del(16q), and del(17p) in SMM consistent with their role as drivers of the transition to MM. KRAS mutations are associated with a shorter time to progression (HR 3.5 (1.5-8.1), p = 0.001). In an analysis of change in clonal structure over time we studied 53 samples from nine patients at multiple time points. Branching evolutionary patterns, novel mutations, biallelic hits in crucial tumour suppressor genes, and segmental copy number changes are key mechanisms underlying the transition to MM, which can precede progression and be used to guide early intervention strategies.
Identifiants
pubmed: 33436579
doi: 10.1038/s41467-020-20524-2
pii: 10.1038/s41467-020-20524-2
pmc: PMC7804406
doi:
Substances chimiques
Biomarkers, Tumor
0
KRAS protein, human
0
APOBEC Deaminases
EC 3.5.4.5
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
293Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Leukemia. 2016 Feb;30(2):417-22
pubmed: 26490489
Leukemia. 2012 Feb;26(2):349-55
pubmed: 21836613
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
BMC Bioinformatics. 2020 Apr 15;21(1):144
pubmed: 32293247
BMC Genomics. 2016 Nov 7;17(1):880
pubmed: 27821060
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):194-204
pubmed: 29222256
Blood. 2007 Oct 1;110(7):2586-92
pubmed: 17576818
Cancer Cell. 2007 Aug;12(2):115-30
pubmed: 17692804
Clin Cancer Res. 2020 May 15;26(10):2422-2432
pubmed: 31988198
J Clin Oncol. 2020 Jul 20;38(21):2380-2389
pubmed: 32442065
Nature. 2011 Aug 10;476(7359):163-9
pubmed: 21833082
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Leukemia. 2013 Aug;27(8):1738-44
pubmed: 23515097
Leukemia. 2013 Apr;27(4):941-6
pubmed: 23183428
Eur J Haematol. 2016 Sep;97(3):303-9
pubmed: 26710662
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
Leukemia. 2020 Jan;34(1):322-326
pubmed: 31439946
Nat Commun. 2019 Aug 23;10(1):3835
pubmed: 31444325
Blood. 2013 Apr 25;121(17):3413-9
pubmed: 23435460
Nat Methods. 2014 Apr;11(4):396-8
pubmed: 24633410
J Clin Oncol. 2010 Mar 20;28(9):1606-10
pubmed: 20177023
Blood Cancer J. 2015 Oct 23;5:e364
pubmed: 26495861
Nat Commun. 2017 Aug 16;8(1):268
pubmed: 28814763
Haematologica. 2015 Sep;100(9):1214-21
pubmed: 26022710
Mayo Clin Proc. 2010 Mar;85(3):300
pubmed: 20194156
Br J Haematol. 2005 Sep;130(5):729-32
pubmed: 16115129
Leukemia. 2014 Feb;28(2):384-390
pubmed: 23817176
N Engl J Med. 2011 Aug 4;365(5):474-5
pubmed: 21812699
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Cancer Res. 2017 Aug 15;77(16):4317-4327
pubmed: 28619709
Nat Commun. 2018 Aug 22;9(1):3363
pubmed: 30135448
Blood Cancer J. 2018 Jun 12;8(6):59
pubmed: 29895887